NONE
Drug
Stryker Corporation
Total Payments
$14.0M
Transactions
8,408
Doctors
2,632
Companies
10
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $89,224 | 93 | 57 |
| 2022 | $19,648 | 6 | 4 |
| 2021 | $24,925 | 26 | 7 |
| 2020 | $2.8M | 1,182 | 468 |
| 2019 | $3.7M | 2,400 | 983 |
| 2018 | $7.4M | 4,698 | 1,418 |
| 2017 | $6,391 | 3 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Gift | $3.8M | 1,013 | 26.9% |
| Education | $2.4M | 200 | 17.2% |
| Unspecified | $2.4M | 144 | 17.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 1,598 | 13.3% |
| Consulting Fee | $1.3M | 906 | 9.6% |
| Grant | $1.2M | 375 | 8.3% |
| Travel and Lodging | $442,271 | 1,004 | 3.2% |
| Space rental or facility fees (teaching hospital only) | $280,165 | 88 | 2.0% |
| Food and Beverage | $175,578 | 3,009 | 1.3% |
| Charitable Contribution | $89,600 | 14 | 0.6% |
| Royalty or License | $42,532 | 10 | 0.3% |
| Honoraria | $34,603 | 47 | 0.2% |
Payments by Type
General
$11.6M
8,264 transactions
Research
$2.4M
144 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Unspecified Research Projects | United Therapeutics Corporation | $504,304 | 1 |
| HUMAN MSC EXOSOME THERAPY FOR BPD INJURY IN THE PRETERM LAMB PRE-CLINICAL MODEL | United Therapeutics Corporation | $300,000 | 0 |
| Whole Genome Sequencing in PAH | United Therapeutics Corporation | $295,880 | 0 |
| PROSPECTIVE DATABASE REGISTRY STUDY OF SCOLIOSIS IN CHILDREN WITH CEREBRAL PALSY | Stryker Corporation | $238,912 | 0 |
| UNSPECIFIED RESEARCH PROJECTS | United Therapeutics Corporation | $223,068 | 8 |
| HUMAN MSC EXOSOME THERAPY TO PROMOTE LUNG GROWTH AND REPAIR IN A NOVEL RAT MODEL OF BRONCHOPULMONARY DYSPLASIA BPD ASSOCIATED WITH PREECLAMPSIA PET AND ANTENATAL INFLAMATION | United Therapeutics Corporation | $179,453 | 0 |
| Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | United Therapeutics Corporation | $98,198 | 4 |
| PROSTACYCLIN RECEPTOR IP AND PROSTACYCLIN SYNTHASE PTGIS EXPRESSION IN SCLERODERMA VASCULAR SMOOTH MUSCLE CELLS VSMCS AND MICROVASCULAR ENDOTHELIAL CELLS MVECS | United Therapeutics Corporation | $91,725 | 0 |
| RETROSPECTIVE STUDY OF OUTCOMES OF PATIENTS WITH GROUPS 1 AND 3 PULMONARY HYPERTENSION TREATED WITH HIGH-DOSE INHALED TREPROSTINIL | United Therapeutics Corporation | $71,179 | 0 |
| Pilot study to evaluate the Utility of equilibrium radionuclide angiography in Pulmonary Arterial Hypertension | United Therapeutics Corporation | $59,760 | 0 |
| PROSPECTIVE, MULTI-CENTER ADULT SPINAL DEFORMITY OUTCOMES DATABASE REGISTRY | Stryker Corporation | $59,317 | 0 |
| EVALN OF PULM PERF HETEROGN & COMPLIANCE IN PTS WITH PAH USING FUNCTIONAL PET IMAGING | United Therapeutics Corporation | $50,605 | 0 |
| MESENCHYMAL STEM CELL EXOSOMES FOR THE REVERSAL OF PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $50,529 | 0 |
| IMPROVING SPINE CARE WITH REAL-TIME OBJECTIVE PATIENT TRACKING | Stryker Corporation | $50,000 | 0 |
| ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | United Therapeutics Corporation | $29,986 | 0 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | United Therapeutics Corporation | $24,466 | 3 |
| SAFETY AND EFFECTIVENESS OF OUTPATIENT TRANSITION FROM INJECTABLE PROSTACYCLIN MEDICATION TO INHALED TREPROSTINIL IN PULMONARY HYPERTENSION | United Therapeutics Corporation | $11,194 | 0 |
| HEALTHRELATED QUALITY OF LIFE INSTRUMENT FOCUSING ON DEPRESSION ANXIETY AND STRESS AS RELATES TO PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $10,873 | 0 |
| A RETROSPECTIVE CASE CONTROL STUDY OF COLLAGEN DURA SUBSTITUTE GRAFTS | Stryker Corporation | $8,500 | 0 |
| MORPHOLOGIC OUTCOMES IN SCAPHOCEPHALY CORRECTION | Stryker Corporation | $6,500 | 0 |
Top Doctors Receiving Payments for NONE — Page 106
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Tung Nguyen | Neurological Surgery | Nashua, NH | $2.57 | 1 |
| , MD | Pulmonary Disease | Wichita, KS | $2.50 | 1 |
| , M.D | Specialist | Dalton, GA | $2.50 | 1 |
| , MD | Internal Medicine | Kansas City, KS | $2.50 | 1 |
| , M.D | Critical Care Medicine | Oklahoma City, OK | $2.50 | 1 |
| , M.D | Interventional Cardiology | Waukesha, WI | $2.50 | 1 |
| , M.D | Cardiovascular Disease | Tulsa, OK | $2.50 | 1 |
| , M.D | Orthopaedic Surgery | Rochester, MN | $1.94 | 1 |
Ad
Manufacturing Companies
- Stryker Corporation $7.6M
- United Therapeutics Corporation $6.3M
- Aesculap Implant Systems, LLC $40,011
- Bioventus LLC $36,570
- Gen-Probe, Inc. $26,179
- LEICA MICROSYSTEMS INC. $24,925
- Aesculap, Inc. $15,284
- Horizon Pharma plc $12,555
- Hologic Sales and Service, LLC $6,104
- B. Braun Medical UK Ltd. $3,568
Product Information
- Type Drug
- Total Payments $14.0M
- Total Doctors 2,632
- Transactions 8,408
About NONE
NONE is a drug associated with $14.0M in payments to 2,632 healthcare providers, recorded across 8,408 transactions in the CMS Open Payments database. The primary manufacturer is Stryker Corporation.
Payment data is available from 2017 to 2024. In 2024, $89,224 was paid across 93 transactions to 57 doctors.
The most common payment nature for NONE is "Gift" ($3.8M, 26.9% of total).
NONE is associated with 20 research studies, including "Unspecified Research Projects" ($504,304).